
HAEMATOLOGY UNDER THE MICROSCOPE

Blood – one of the many things that keeps the human body alive, but also the source of many life-threatening diseases. This infographic explores the vastness of the haematology market, including key industry players, drugs to watch, the global burden of haematological diseases and more

BREAKDOWN OF THE HAEMATOLOGY MARKET (2022)



Market share by region



Source: Global Market Insights, 2023

HAEMATOLOGY DRUGS TO WATCH IN 2023

Daprodustat

Company: GSK

Usage: CKD-related anaemia Launch: 2020 (Japan)

Expected launch: 2023 (US and Europe)

Probability of success for daprodustat in the US:

95%

Valoctocogene roxaparvovec

BIOMARIN

Company: Biomarin Usage: Haemophilia A Launch: 2022 (Europe)

Expected Launch: Expected launch: 2023 (US)


Probability of success for

valoctocogene roxaparvovec in the US:



Source: Clarivate, 2023

HAEMOPHILIA FOCUS



Approximately
1 in 6,000 males
have haemophilia A

GSK



Source: Haemophilia Foundation, 2023

There is a median diagnostic delay of:




Source: World Federation of Haemophilia, 2023

Around **75**% of people with haemophilia live in the developing world

Source: National Library of Medicine, 2023

BLOOD CANCER FOCUS

The five-year survival rate for blood cancer is:



The three most common types of blood cancer in the UK:

- Diffuse large B-cell lymphoma (affects 5,500 people a year)
- 2. Chronic lymphocytic leukaemia (affects 4,700 people a year)
- 3. Myeloma (affects 4,500 people a year)

Source: bloodcancer.org, 2022

Blood cancer incidence rates are highest in:





Western Europe

0000